ERK

Eras-4001 is a potent, orally active pan- KRAS inhibitor with K d values of 110, 13 and 39 pM against wild-type, G12D and G12V mutant KRAS, respectively, and exhibits selectivity toward wild-type HRAS and NRAS.

KRAS G12D-IN-30 (Compound 4) is a KRAS inhibitor.

HTL-9936 is an orally active partial agonist of muscarinic M1 receptor.

HDB-1 is a selective inhibitor of the P2Y14 receptor ( P2Y14R ) with an IC 50 of 26 pM.

ETI41 is an orally active, selective TLR inhibitor that targets the nucleoside-binding Site I on TLR7 ( IC 50 = 0.63 μM) and TLR9 ( IC 50 = 0.16 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5).

ETI60 is an orally active, selective TLR inhibitor that targets the nucleoside-binding Site I on TLR7 ( IC 50 = 0.68 μM) and TLR9 ( IC 50 = 0.12 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5).

IL13Rα2 D1 is an effective IL-13/IL13Rα2 signaling axis inhibitor.

Anti-IL11 Antibody (X203, Mouse IgG ) is an antibody targeting IL-11.

Anti-Human/Mouse Amphiregulin Antibody (AR37) is an antibody targeting amphiregulin ( AREG ), with a K d value of 3.24 nM for the human protein and 6.40 nM for the mouse protein.

AZ14289671 is an orally active, blood-brain barrier-penetrant tyrosine kinase ( tyrosine kinase ) inhibitor (TKI) that specifically targets non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations ( EGFR Exon20Ins ), while largely sparing wild-type EGFR to reduce off-target toxicities such as rash and diarrhea.

KZ-02 is an orally active dual MEK1 / Pim-1 kinase inhibitor, with an IC 50 of 1.07 nM against MEK1 and an IC 50 of 1.34 μM against Pim-1.

IK-595 is a MEK1/MEK2 inhibitor with high affinity (7.39 nM).IK-595 blocks EGF-induced ERK1/2 phosphorylation in AsPC-1 cells with IC 50 value of 0.1 nM.

MD-3-A45 is an inhibitor of fibroblast growth factor 23 ( FGF-23 ).

APS03118 is an orally active, potent and selective rearranged during transfection ( RET ) inhibitor.

ST1072 is an inhibitor of CerS4 and CerS6.

Alcudacigib (ASP1570; DGKζ-IN-1) TFA is an orally active diacylglycerol kinase ζ ( DGKζ ) inhibitor, with an IC 50 of 4.7 nM against human DGKζ and an IC 50 of 3.0 nM against mouse DGKζ. Alcudacigib TFA selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein.

Tyrosine kinase-IN-11 (Compound 4b) is a tyrosine kinase inhibitor.

PDGFRA/CAIX/XII-IN-1 is an inhibitor of PDGFRA, CA IX and CA XII, with an IC 50 of 20 nM against PDGFRA, a K i of 93.3 nM against CA IX, and a K i of 80.0 nM against CA XII.

FGF7p is a small molecule peptide and a potential bladder protector.

VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold.

GZD-552 is a potent orally active FAK inhibitor with a human FAK IC 50 of 5.8 nM.

TCB-32 (Compound I-1) hydrochloride is a FGFR1 agonist with an EC 50 of 0.88 μM.

BTX-6654 formate is a SOS1 PROTAC degrader.

SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor.